Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ida Cedrych"'
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4507-4518 (2024)
Background: Mass-forming intrahepatic cholangiocarcinoma (mICC) is the most frequent type of ICC. In contrast-enhanced computed tomography, mICC is visualized as a hypodense lesion with distal dilatation of intrahepatic bile ducts. The presented case
Externí odkaz:
https://doaj.org/article/54771ad8d032457c9351281d7459294c
Publikováno v:
Menopause Review, Vol 19, Iss 2, Pp 72-79 (2020)
Externí odkaz:
https://doaj.org/article/53996be7f904411397438f1df076243a
Autor:
Ida Cedrych, Maksymilian A. Kruczała, Tomasz Walasek, Jerzy Jakubowicz, Paweł Blecharz, Marian Reinfuss
Publikováno v:
Contemporary Oncology, Vol 20, Iss 5, Pp 352-357 (2016)
In the systemic treatment of brain metastases from non-small cell lung cancer (BMF-NSCLC) chemo- and targeted therapy are used. Response rates after platinum-based chemotherapy, range from 23% to 45%. Development of epidermal growth factor receptor t
Externí odkaz:
https://doaj.org/article/407629ac5da049baab47853e85575706
Publikováno v:
Menopause Review, Vol 19, Iss 2, Pp 72-79 (2020)
Przegla̜d Menopauzalny = Menopause Review
Przegla̜d Menopauzalny = Menopause Review
Introduction High social cost and high risk of disability make postmenopausal osteoporosis one of major public health problem in the 21st century. The aim of this study was to assess frequency of undiagnosed and untreated osteoporosis in postmenopaus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba380d0299a64bb1a6921b0f16415ad8
https://www.termedia.pl/High-rates-of-undiagnosed-and-untreated-osteoporosis-in-postmenopausal-r-nwomen-receiving-medical-services-in-the-area-of-Upper-Silesia,4,41488,1,1.html
https://www.termedia.pl/High-rates-of-undiagnosed-and-untreated-osteoporosis-in-postmenopausal-r-nwomen-receiving-medical-services-in-the-area-of-Upper-Silesia,4,41488,1,1.html
Autor:
Ewa Cedrych, Ida Cedrych
Publikováno v:
Oncology in Clinical Practice. 15:111-114
Neratinib is a new small molecule aimed at HER2 receptor. It has recently been approved in the United States of America and Europe for adjuvant treatment of patients with early, HER2-positive breast cancer, who underwent surgical resection followed b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::816cfe02ba3bac716780ea8445bce838
https://doi.org/10.5603/ocp.2019.0014
https://doi.org/10.5603/ocp.2019.0014
Autor:
Anna Kruczak, Małgorzata Domagała-Haduch, Aleksandra Ambicka, Agnieszka Harazin-Lechowska, Agnieszka Adamczyk, Anna Janecka, Aleksandra Grela-Wojewoda, Janusz Ryś, Ida Cedrych, Joanna Niemiec, Kaja Majchrzyk
Publikováno v:
Journal of Cancer
Aim: Resistance to trastuzumab (which is a standard therapy for breast cancer patients with HER2 overexpression) is associated with higher risk of progression or cancer death, and might be related to activation of signalling cascades (PI3K/AKT/mTOR,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af8ba13c0acab709ea1b367e20b772db
http://europepmc.org/articles/PMC5264049
http://europepmc.org/articles/PMC5264049
Publikováno v:
Archives of Medical Science : AMS
Introduction Treatment of the metastatic stage of renal cell carcinoma is specific because classical chemotherapy is not applicable here. The treatment is mainly based on molecularly targeted drugs, including inhibitors of tyrosine kinases. In many c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cdd224195f880802db6bc103a373cda
https://doi.org/10.5114/aoms.2016.59262
https://doi.org/10.5114/aoms.2016.59262
Publikováno v:
Polish Gynaecology. 87:131-134
Treatment of the malignant ovarian tumors remains challenging. Some of the reasons are as follows: lack of effective screening technique, usually asymptomatic early stages of the disease, which effects in detecting the disease in advanced stage, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be9a30ed2cd9a528c54e1c8740a152b5
https://doi.org/10.17772/gp/59268
https://doi.org/10.17772/gp/59268
Publikováno v:
OncoReview. 5:133-138
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::38df6b661c22192277da2d1899dc4e9e
https://doi.org/10.5604/20828691.1171802
https://doi.org/10.5604/20828691.1171802
Publikováno v:
Oncoreview. 6
Introduction: Bevacizumab is an antiangiogenic drug used in the therapy of numerous solid tumours including colorectal adenocarcinoma. The efficacy and safety of bevacizumab has been demonstrated in many multicenter clinical trials. The scope of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5e19493f12c4eaa51d85ac6163d9e04
https://doi.org/10.5604/01.3001.0009.5069
https://doi.org/10.5604/01.3001.0009.5069